China has been neglected for a long time and is a sleeping giant. Domestic technology champions are emerging, policy prioritizes innovation, valuations remain reasonable, and there are structural earnings growth opportunities in Chinese tech, AI, data, open-source models, and industrial/humanoid robots.
India is an anti-AI trade with smaller AI exposure but many structural opportunities: consumption, favorable demographics, strong car sales growth, and financials. Foreign institutions are returning since mid-June, ownership is at a 20-year low, and HSBC is overweight consumer discretionary and financials.
India is an anti-AI trade with smaller AI exposure but many structural opportunities: consumption, favorable demographics, strong car sales growth, and financials. Foreign institutions are returning since mid-June, ownership is at a 20-year low, and HSBC is overweight consumer discretionary and financials.
Chinese biotech evolved into drug-development partner.
China's healthcare sector, specifically biotech, has been neglected in the first half but is getting interesting. China has evolved from a low-cost research hub to a partner in drug development and manufacturing, and HSBC is positive on some Chinese players.